News

Bridging Study Finds Ripretinib Improves Survival Among Chinese Patients With Advanced Gastrointestinal Stromal Tumors

07/08/2022

In a phase 2 bridging study of the phase 3 INVICTUS study, ripretinib was found to improve the survival of Chinese patients with advanced gastrointestinal stromal tumors.

In a phase 2 bridging study of...

07/08/2022

Oncology

News

Pimitespib Improves Survival for Patients With Advanced GIST: CHAPTER-GIST-301 Trial

06/15/2022

Allison Casey ;

Results from a phase 3 CHAPTER-GIST-301 trial show pimitespib significantly improved PFS and crossover-adjusted OS vs placebo for patients with advanced GIST refractory to TKIs.

Results from a phase 3...

06/15/2022

Oncology

News

Long-term Outcomes of Endoscopic Therapy vs Surgical Resection for Gastrointestinal Stromal Tumors

05/04/2022

Janelle Bradley ;

Study findings reveal no significant difference in long-term survival among patients with gastrointestinal stromal tumors receiving endoscopic therapy vs surgical resection.

Study findings reveal no...

05/04/2022

Oncology

News

Imatinib Plus Binimetinib Found Effective With Manageable Toxicity in Advanced GIST

02/24/2022

The results of a phase 2 trial which evaluated the efficacy and safety of imatinib plus binimetinib in first-line treatment of advanced gastrointestinal stromal tumor (GIST) warranted the comparison of the novel strategy to imatinib alone.

The results of a phase 2 trial...

02/24/2022

Oncology

News

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in GIST

02/24/2022

Study findings reveal avapritinib is not superior to regorafenib for the third-line or later treatment of gastrointestinal stromal tumors (GISTs).

Study findings reveal...

02/24/2022

Oncology

Conference Coverage

Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape

09/14/2021

The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.

The ESMO-MCBS medical device was...

09/14/2021

Oncology

Conference Coverage

Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape

09/14/2021

The ESMO-MCBS medical device was...

09/14/2021

Oncology

Conference Coverage

Driver Mutations Found Targetable for Wild-Type GIST

09/14/2021

Findings from a recent study were shared at the virtual 2021 ESMO Congress to present identifiable, targetable driver mutations for wild-type mutations in GIST and gain insight into developing corresponding targeted therapies.

Findings from a recent study...

09/14/2021

Oncology

Conference Coverage

Driver Mutations Found Targetable for Wild-Type GIST

09/14/2021

Findings from a recent study...

09/14/2021

Oncology

Conference Insider

Phase 3 INVICTUS Trial Demonstrates Ripretinib Benefit in GIST

09/14/2021

Mature data released from the phase 3 INVICTUS trial yields significantly improved PFS, reductions in disease progression, and clinically meaningful OS improvements in advanced gastrointestinal stromal tumors (GIST), presented at the virtual...

Mature data released from the...

09/14/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology